RARX News and Press, Ra Pharmaceuticals Inc. From 08/07/19

Initiation of single, pivotal, 12-week, Phase 3 gMG clinical trial on track for the second half of 2019 Initiation of multi-center, Phase 2 IMNM clinical trial on track for the second half of 2019 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the s...

Achillion Pharmaceuticals ( ACHN ) had achieved a massive surge in stock price recently. It all started when it had reported positive data from a phase 1 study using its drug ACH-5228. This data was early, but investors were optimistic based on the initial findings of the impressive sustai...

KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Outperform rating and $31 (83% upside) price target at SVB Leerink. More news on: KalVista Pharmaceuticals, Inc., Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...

Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.50 per share, including 600,000 shares sold pursuant to the underwriters’ exerci...

Ra Pharmaceuticals (NASDAQ: RARX ) has announced it plans to offer $100M in common stock in an underwritten public offering. More news on: Ra Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...

Ra Pharmaceuticals (NASDAQ: RARX ) inks a global license agreement with Camurus AB ( OTC:CAMRF ) securing the rights to the latter's FluidCrystal technology that will enable the development of a long-acting formulation of C5 inhibitor zilucoplan for the treatment of complement-mediated dis...

FluidCrystal® extended release formulation of zilucoplan achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting at least once weekly dosing Ra Pharmaceuticals, Inc. (Nasdaq:RARX) and Camurus AB (Nasdaq STO:CAMX) today announced a...

I’ve been pleased with how Ra Pharmaceuticals ( RARX ) has navigated the clinical program changes over the last 12 months. The stock is up quite a bit since I wrote a positive piece almost a year ago, though I have watched the stock deliver the gains from the sidelines. Most, if not...

The following slide deck was published by Ra Pharmaceuticals, Inc. in conjunction with this Read more ...